TWI BIOTECHNOLOGY, INC.

Andere Sprachen TWi Biotechnology, Inc.

Aktien

6610

TW0006610009

6610

Schlusskurs Taipei Exchange Andere Börsenplätze 00:00:00 03.06.2024			% 5 Tage	% 1. Jan.
12,7 ^TWD	+0,79 %		+3,67 %	-9,29 %

09.04.	TWi Biotechnology, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	TWi Biotechnology, Inc. meldet Ergebnis für das Halbjahr bis zum 30. Juni 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09.04.
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	14.08.23
TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)	02.06.23
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	26.04.23
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	12.08.22
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	28.04.22
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	15.08.21
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203	07.01.21
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	12.08.20
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA	07.05.20
Twi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	09.04.19
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy	15.11.18
TWi Biotechnology, Inc. Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	20.10.18
TWi Biotechnology, Inc. Announces Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	26.02.18
TWi Biotechnology Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment	27.06.16
TWi Biotechnology, Inc. Enters Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals	22.12.15
TWi Biotechnology, Inc. Completes Multinational Phase II Dose-Ranging Study of AC-201	06.08.12

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.

PROFITIEREN SIE JETZT